Shilpa Medicare Ltd - Company Profile
Powered by 
All the sales intelligence you need on Shilpa Medicare Ltd in one solution.
- Save hours of research time with a comprehensive
Sales Intelligence Solution.
- Understand how Shilpa Medicare Ltd fits into your total
addressable market and Ideal Customer Profile.
- Gain competitive edge with triggers that tell you
when and how to engage with Shilpa Medicare Ltd.
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward
Shilpa Medicare Ltd (Shilpa Medicare) develops, manufactures, and markets a broad range of generic pharmaceutical products, including active pharmaceutical ingredients (APIs), formulations, new drug delivery systems, peptides, specialty chemicals, and intermediates. The company offers oncology and non-oncology APIs and produces high-quality oral solids, liquid injections, and lyophilized injectables. It operates production facilities across India specializing in complex APIs, formulations, biologicals, and novel drug-delivery systems. Shilpa Medicare is also advancing its biologicals and biosimilars portfolio, including monoclonal antibodies, microbial biosimilars, vaccines, and recombinant human albumin. The company also provides contract research and manufacturing services (CDMO) for global clients. Shilpa Medicare is headquartered in Raichur, Karnataka, India.
Headquarters
India
Address
#12-6-214/A1, Hyderabad Road, Raichur, Karnataka, 584135
Website
www.vbshilpa.com
Telephone
91 8532 235006
No of Employees
898
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
SHILPAMED (NSE)
Revenue (2025)
$176.6M
19.6%
(2025 vs 2024)
EPS
XYZ
Net Income (2025)
XYZ
210.8%
(2025 vs 2024)
Market Cap*
$1.2B
Net Profit Margin (2025)
XYZ
159.6%
(2025 vs 2024)
* As of and is in US$
Shilpa Medicare Ltd premium industry data and analytics
Products and Services
| Products | Services |
|---|---|
| Active Pharmaceutical Ingredients | Contract Development and Manufacturing Organization (CDMO) Services |
| Formulations: | |
| Injectable Dosage Forms | |
| XYZ | |
| XYZ | |
| XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2025 | Contracts/Agreements | In October, the company entered into an agreement to sell a 31% stake in Sravathi Advance Process Technologies Pvt Ltd to Ash Ingredients Inc and Varcatalyst LLP. |
| 2025 | Corporate Changes/Expansions | In May, Shilpa Biologicals opened a bioconjugation suite at its Dharwad site in India. |
| 2023 | Acquisitions/Mergers/Takeovers | In November, the company announced the acquisition of Pilnova Pharma Inc. |
Competitor Comparison
| Key Parameters | Shilpa Medicare Ltd | Lupin Ltd | Glenmark Pharmaceuticals Ltd | Natco Pharma Ltd | J B Chemicals and Pharmaceuticals Ltd |
|---|---|---|---|---|---|
| Headquarters | India | India | India | India | India |
| City | Raichur | Mumbai | Mumbai | Hyderabad | Mumbai |
| State/Province | Karnataka | Maharashtra | Maharashtra | Telangana | Maharashtra |
| No. of Employees | 898 | 19,021 | 13,477 | 4,199 | 5,517 |
| Entity Type | Public | Public | Public | Public | Public |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Omprakash Inani | Chairman | Executive Board | 1988 | 68 |
| Kalakota Sharath Reddy | Director; Vice President - Projects and Operations | Executive Board | 2019 | 57 |
| Vishnukant Chaturbhuj Bhutada | Managing Director | Executive Board | - | - |
| Alpesh M. Dalal | Chief Financial Officer | Senior Management | - | - |
| R. K. Somani | Vice President - Formulations Business | Senior Management | - | - |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer